Cannabis Wire had a far-ranging interview with Cannabis Control Board Chair Tremaine Wright ahead of tomorrow's expected licensing push. Wright reflected on recent challenges, from lawsuits to criticisms, and the year ahead. cannabiswire.com/2024/02/15/new…

The U.S. FDA Center for Drug Evaluation & Research released a new report on its '23 priorities. In it they detail some of their work that led to HHS.gov recommendation that cannabis move to Schedule III. That + more in the Cannabis Wire Daily newsletter: cannabiswire.com/2024/02/16/u-s…

Australian lawmakers held their first hearing this week on a bill to legalize cannabis for adults. “The horse has bolted on this issue, and it’s because of the failure of criminalization,” said Greg Barns, former nat'l president of AU_LawyersAlliance. cannabiswire.com/2024/02/22/aus…

During its annual report launch this week, in response to a question about Germany’s legalization plans, the president of the International Narcotics Control Board said it's up to the international community to decide on legal cannabis “once and for all.” cannabiswire.com/2024/03/06/uni…

The topics that got the most airtime at the latest meeting of California’s Cannabis Advisory Committee weren’t on the agenda: the sprawl of intoxicating hemp products, and the unlicensed cannabis market. cannabiswire.com/2024/03/11/cal…

Pew research again finds high (9 in 10) support for legal cannabis. But support has shifted a bit. In 2022, 59% said cannabis should be legal for medical and adult use. This year, that fell to 57%, while support for medical use only rose from 30% to 32%. cannabiswire.com/2024/03/28/pew…

Do federal officials at OSHA_DOL think about cannabis workplace safety? Quite a bit. In a rare cannabis-focused session from the agency, two OSHA officials on Tuesday shared their latest insights on potential hazards and best practices. cannabiswire.com/2024/04/16/osh…

🤔🌿💨 Wonder what OSHA thinks about the workplace hazards associated with the cannabis industry? Check out this article on a discussion with an OSHA industrial hygienist and a medical officer who share guidance on protecting workers.

Over time, more mainstream companies are lobbying on cannabis, like Amazon and American Express (which Cannabis Wire first reported). This week we spotted a new one: Haleon US, maker of Sensodyne. That and more in the Cannabis Wire Daily newsletter: cannabiswire.com/2024/04/24/new…

In a historic move, the DEA will recommend that cannabis be reclassified as a medicine, according to The Associated Press. Once the process is complete, it will mark an historic shift in U.S. cannabis policy, and is likely to send ripple effects across the globe. cannabiswire.com/2024/04/30/dea…

SCOOP: our story is updated to include more about the expected memo.

Today, New York Governor Kathy Hochul announced an “overhaul” at the Office of Cannabis Management. She also said OCM exec. director Chris Alexander will step down. cannabiswire.com/2024/05/10/new…

Today, President Biden and U.S. Department of Justice formally announced next steps in the process to reclassify cannabis and recognize its medical use. Next step: public comment. An important legal memo, first reported in April by Cannabis Wire, was also published today. cannabiswire.com/2024/05/16/pre…

From Congress to Iowa and Colorado, new battles brew over intoxicating hemp cannabiswire.com/2024/06/20/fro…

We sat down w/ Earl Blumenauer before he retires to talk about current cannabis debates in Congress. On efforts to ban intoxicating hemp products: it "slipped into legislation that didn’t get a lot of the spotlight" and is "more or less below the radar." cannabiswire.com/2024/06/25/can…

New York cannabis regulators recently issued a notice about unlicensed events. But are they enforcing, we asked? “As of now illicit shops are the focus and no unlicensed events have received an enforcement notice,” a spokesperson told us. cannabiswire.com/2024/06/26/new…

What do transportation entities have to say about rescheduling? AAA and NTSB commented on the Biden administration’s proposal to move cannabis from Schedule I to Schedule III of the CSA. Some offered support, while most urged caution. cannabiswire.com/2024/07/23/tra…

What do medical & research entities have to say about rescheduling? AMA & University of California commented on Biden's proposal to move cannabis from Schedule I to Schedule III of the CSA. Some called for funding, others for clarity on cannabinoids. cannabiswire.com/2024/07/23/med…